UBS AM
PHVS icon

UBS AM’s Pharvaris PHVS Stock Holding History

UBS AM’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.19M Sell
77,646
-6,301
-8% -$168K ﹤0.01% 2005
2025
Q4 		$2.33M Buy
+83,947
New +$2.02M ﹤0.01% 1827
2025
Q3 		– Sell
-55,377
Closed -$975K – 2516
2025
Q2 		$975K Sell
55,377
-12,954
-19% -$209K ﹤0.01% 2392
2025
Q1 		$1.07M Buy
68,331
+4,597
+7% +$77.5K ﹤0.01% 2274
2024
Q4 		$1.22M Buy
63,734
+14,838
+30% +$305K ﹤0.01% 2290
2024
Q3 		$906K Buy
+48,896
New +$893K ﹤0.01% 2446

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $1.02B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

UBS AM's PHVS Position: Q1 2026 in Review

UBS AM reduced its Pharvaris (PHVS) stake by 7.5% in Q1 2026, selling an estimated $168K and leaving 77,646 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2005.

UBS AM first reported a position in PHVS in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.33M in Q4 2025. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

  • UBS AM held 77,646 shares of Pharvaris worth $2.19M as of Q1 2026.
  • UBS AM sold 6,301 Pharvaris shares in Q1 2026, an estimated $168K.
  • Pharvaris made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2005 holding.
  • UBS AM first reported a position in Pharvaris in Q3 2024 and has held it in 6 quarters since.
  • UBS AM's Pharvaris position peaked at $2.33M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.